Skip to main content

Paul Langlie Martin, MD, PhD

Professor of Pediatrics
Chief, Division of Pediatric Blood and Marrow Transplantation
Member of the Duke Cancer Institute
Campus mail: 1400 Morrene Rd, Durham, NC 27705
Phone: (919) 668-1124
Email address: paul.martin@duke.edu

For most of my career in Pediatric Hematology/Oncology I have focused on the use of stem cell transplant for the treatment of pediatric leukemias (ALL, AML, CML and JMML) and other non-malignant blood disorders, such as thalassemia, hemaphagocytic disorders, Wiskott-Aldrich, aplastic anemia, Diamond-Blackfan Anemia, as well as inherited metabolic diseases. In addition to focusing on determining the best use of stem cell transplants for these disorders, I have also been involved in clinical research investigating the prevention and treatment of transplant related morbidity, particularly veno-occlusive disease of the liver, infections and diffuse alveolar hemorrhage. As study chair for the Children's Oncology Group protocol 9904, I was involved in the development, implementation and analysis of a large, international frontline study of childhood acute lymphoblastic leukemia. Results from this study show that a significant number of children with certain favorable cytogenetic abnormalities in their leukemic cells and who have a rapid response to their initial chemotherapy can expect to have a >95% chance of cure when treated with relatively low intensity chemotherapy.  

For most of my time at Duke I have concentrated on providing high quality care for high risk leukemia patients who require high intensity therapies, such as stem cell transplant and immunotherapy.  As a member of the Pediatric Transplant and Cellular Therapy Division I provide clinical care for these patients.  As a member of various cooperative groups and local PI for several drug trials, I have worked to provide better care and more specific therapies for the toxicities associated with stem cell transplant.  

I have also collaborated with the Pediatric Immunology Division to provide a life-saving therapy for a small group of patients with thymic dysfunction, which causes severe immunodeficiency.  Our clinical team now provides support during these patients hospital admissions for donor thymus tissue implantation.

Education and Training

  • Fellow, Pediatric Hematology/Oncology, Pediatrics, Yale University, 1989 - 1992
  • Resident, Pediatrics, Yale University, 1988 - 1989
  • Intern, Pediatrics, Yale University, 1987 - 1988
  • Ph.D., Washington University in St. Louis, 1987
  • M.D., Washington University in St. Louis, 1987

Publications

Hall, Jennifer G., Paul L. Martin, Susan Wood, and Joanne Kurtzberg. “Unrelated umbilical cord blood transplantation for an infant with beta-thalassemia major.” J Pediatr Hematol Oncol 26, no. 6 (June 2004): 382–85. https://doi.org/10.1097/00043426-200406000-00010.

Full Text

Staba, Susan L., Maria L. Escolar, Michele Poe, Young Kim, Paul L. Martin, Paul Szabolcs, June Allison-Thacker, et al. “Cord-blood transplants from unrelated donors in patients with Hurler's syndrome.” N Engl J Med 350, no. 19 (May 6, 2004): 1960–69. https://doi.org/10.1056/NEJMoa032613.

Full Text

Staba, S. L., P. Szabolcs, T. Driscoll, P. L. Martin, and J. Kurtzberg. “Second hematopoietic stem cell transplant using unrelated donor umbilical cord blood cures 50% of pediatric patients with leukemia relapsing after prior allogeneic transplant from a matched related sibling.” In Biology of Blood and Marrow Transplantation, 10:38–38. Elsevier BV, 2004. https://doi.org/10.1016/j.bbmt.2003.12.179.

Full Text

Allison, J., P. L. Martin, P. Szabolcs, T. Driscoll, S. Parikh, S. Wood, and J. Kurtzberg. “Transplantation of boys with X-linked adrenoleukodystrophy with unrelated-donor, partially HLA-mismatched banked umbilical cord blood.” In Biology of Blood and Marrow Transplantation, 10:74–74. Elsevier BV, 2004. https://doi.org/10.1016/j.bbmt.2003.12.100.

Full Text

Archambault, B. L., T. A. Driscoll, L. A. Stafford, P. Szabolcs, J. Kurtzberg, and P. L. Martin. “Unrelated umbilical cord blood transplantation for familial erythrophagocytic lymphohistiocytosis.” In Biology of Blood and Marrow Transplantation, 10:79–80. Elsevier BV, 2004. https://doi.org/10.1016/j.bbmt.2003.12.132.

Full Text

Steinbach, W. J., W. A. Schell, J. L. Miller, J. R. Perfect, and P. L. Martin. “Fatal Scopulariopsis brevicaulis infection in a paediatric stem-cell transplant patient treated with voriconazole and caspofungin and a review of Scopulariopsis infections in immunocompromised patients.” J Infect 48, no. 1 (January 2004): 112–16. https://doi.org/10.1016/s0163-4453(03)00134-8.

Full Text

Richardson, P., R. J. Soiffer, J. H. Antin, Z. Jin, J. J. Vredenburgh, J. Kurtzberg, P. L. Martin, et al. “Defibrotide (DF) is effective in the treatment of severe veno-occlusive disease (VOD) and multi-system organ failure (MOF) post stem cell transplantation (SCT): Results of a phase II, multicenter, randomized study.” In Blood, 102:193A-193A. AMER SOC HEMATOLOGY, 2003.

Scholars@Duke

Kurtzberg, J., P. Szabolcs, P. L. Martin, T. Driscoll, T. Kelly, G. Ciocci, and M. L. Escolar. “Unrelated donor umbilical cord blood transplantation for X-linked adrenoleukodystrophy.” In Blood, 102:479B-479B. AMER SOC HEMATOLOGY, 2003.

Scholars@Duke

Jaroscak, Jennifer, Kristin Goltry, Alan Smith, Barbara Waters-Pick, Paul L. Martin, Timothy A. Driscoll, Richard Howrey, et al. “Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System.” Blood 101, no. 12 (June 15, 2003): 5061–67. https://doi.org/10.1182/blood-2001-12-0290.

Full Text

Gururangan, Sridharan, Colleen McLaughlin, Jennifer Quinn, Jeremy Rich, David Reardon, Edward C. Halperin, James Herndon, et al. “High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas.” J Clin Oncol 21, no. 11 (June 1, 2003): 2187–91. https://doi.org/10.1200/JCO.2003.10.096.

Full Text

Pages